Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

por Arendt, A.-M., Heubach, F., Maier, C. P., Giardino, S., Jung, G., Kowalewski, E., Rabsteyn, A., Amorelli, G., Seitz, C., Schlegel, P., Handgretinger, R., Lang, P.
Publicado 2023